Cleveland Clinic Cancer Advances
Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab
02 May 2024
Description
Shilpa Gupta, MD, Director of the Genitourinary Oncology Program at Cleveland Clinic Cancer Institute, provides an overview of the clinical trial of enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. Listen as Dr. Gupta talks about the exciting results of the trial, which showed that the combination therapy was effective for both cisplatin-eligible and cisplatin-ineligible patients. She also highlights the future studies that are being conducted to explore the use of the therapy in the neoadjuvant setting.
Audio
Featured in this Episode
No persons identified in this episode.
Transcription
No transcription available yet
Help us prioritize this episode for transcription by upvoting it.
0
upvotes
Popular episodes get transcribed faster